Jan 06, 2020
CStone Pharmaceuticals and Blueprint Medicines Initiate Phase 1b/2 Clinical Trial of Fisogatinib in Combination with CS1001 for Patients with Hepatocellular Carcinoma
Nov 18, 2019
Medivir Reports Last Patient Recruited to the Phase Ia Study of MIV-818 in Liver Cancer Patients and Initial Dose Determined for phase Ib
Nov 12, 2019
Laboratory for Advanced Medicine Presents New Liver Cancer Test Data at The Liver Meeting 2019
Nov 06, 2019
DURECT to Host Key Opinion Leader Call on DUR-928 Phase 2a Alcoholic Hepatitis Study Results
Nov 05, 2019
Liver Cancer Diagnostic Market to be Driven by Rising Prevalence of Liver Cancer Owing to Unhealthy Eating & Drinking Habits Till 2025 | Million Insights
Oct 30, 2019
Medivir Presents MIV-818 Data at AACR-NCI-EORTC in Boston
Oct 22, 2019
HighTide Therapeutics Announces Completion of Enrollment in Phase 2a NASH Study of HTD1801
Oct 22, 2019
OrigiMed: The largest cohort study on HBV-Related hepatocellular carcinoma in China released in Cell
Oct 16, 2019
Sirtex Medical appoints Kevin R. Smith as Chief Executive Officer
Oct 16, 2019
Hepagene Therapeutics, Inc, Announces Dosing of First Healthy Subject in a Phase I Study of HPG1860 for NASH
Oct 10, 2019
Data to be Presented at AASLD 2019 Shows HighTide Lead Compound Improves NASH in Two Animal Models
Sep 24, 2019
Eisai Announces Data Presentations on KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Investigational Combination Therapy and HALAVEN® (eribulin) at ESMO 2019
Sep 11, 2019
Q Biomed and Collaborator Chemveda Life Sciences Enter Agreement for Synthesis and Manufacturing of Liver Cancer Chemotherapeutic
Aug 27, 2019
Ionis licenses hepatitis B program to GSK
Aug 22, 2019
Snap Bio's Lead Candidate Overcomes Resistance of Approved Drugs for Liver Cancer
Aug 20, 2019
Q BioMed and Collaborator Chemveda Life Sciences Announce Potential Chemotherapeutic Breakthrough in Liver Cancer
Aug 08, 2019
Laboratory for Advanced Medicine Strengthens Hepatology Board with Addition of Three Distinguished Medical Doctors
Aug 08, 2019
89bio Initiates Phase 1b/2a Proof of Concept Clinical Trial of Investigational Therapy BIO89-100 for the Treatment of NASH
Aug 02, 2019
SillaJen Announces Conclusions From Interim Futility Analysis Of Phase 3 PHOCUS Trial in HCC
Jul 23, 2019
Recommendations for Personalised HCC Treatment With Y90 TheraSphere(TM) Published by an International Multidisciplinary Group